![origenis_logo_Pantone [Konvertiert]_2020](https://static.wixstatic.com/media/9afeac_83ea95f8f63144538d48a310b96d7f33~mv2.png/v1/fill/w_260,h_53,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/origenis_logo_Pantone%20%5BKonvertiert%5D_2020.png){kind=logo}
Leadership
Where no one has gone before
Executive Management
Dr Michael Thormann, CEO & CSO
Michael Thormann is co-founder and co-inventor of MOREsystem® and MolMind®. He leads the technology platform development, implementation, and its application throughout the drug discovery and development process. As CSO, he is responsible for the success of the cross-functional, highly interdisciplinary team and empowers scientific excellence and technological leadership, and industrial applicability. Prior Origenis, as Head of Molecular Modeling at Morphochem, he invented protein- and ligand-based drug design methods, QSPR, parallel evolutionary search algorithms, and multiparametric optimization techniques, that together with Cippix® and BRAINstorm® have lead to Origenis’ proprietary AI Innovation Platform. He received his Ph.D. in biochemistry from the University of Leipzig in 1998. He worked in the field of secondary structure design and conformational analysis of special non-natural peptides and held several post-doctoral positions at the University of Barcelona and Polytechnical University of Catalonia.
Dr Andreas Treml, COO
Andreas Treml helms and oversees business operations, HR and manages budget and financial goals. As co-founder of Origenis he is contributing biological expertise to the management team. In prior positions he was responsible for assay development and integrating ‘New Technologies’ for parallel biological characterization. Andreas holds a Ph.D. in biology and worked in the field of steroid hormone receptors and transcription factors for therapeutic oncology and across multiple therapeutic target areas during industrial and academic collaborations.
Senior Management
Michael Almstetter,
Chief Strategist
Cofounder of Origenis in 2005, leading the company through growth and private financing rounds, Michael created the basis for the later MOREsystem® with the invention of MolMind®. He also is responsible for the development of parallel chemistry, automated synthesis and analytics. He studied chemistry at the Technical University of Munich at the Organic Chemistry department of Prof. Dr. Ivar Ugi.
Dr Gergana Galabova,
VP Translational Medicine
Gergana Galabova is responsible for the pre-clinical research and development and the translation of R&D results from the Origenis Technology Platform into therapeutic areas with unmet medical needs. Gergana graduated Veterinary Medicine at Trakia University, holds Doctoral Degree from Vet Med Uni Vienna, with focus animal histology and histopathology and has six years post-doctoral experience, with focus on the in vivo and in vitro deciphering of the MAPK Kinase Pathway from the Max F. Perutz Laboratories, University of Vienna. Gergana is a former employee and Head of the Neurodegeneration Department of AFFIRIS AG, Vienna. She has more than 10 years’ experience in the field of vaccine pre-clinical and clinical research and development and has successfully translated several pre-clinical therapeutic and biomarker programs into clinical settings and clinical endpoints. Gergana joined Origenis in 2018 as VP Translational Medicine.
Dr Roland Köstler, Director Chemistry
Roland Köstler leads the chemistry team at Origenis. He is responsible for the design of novel compound classes, the development of their synthetic routes and involved in the IP protection. Additionally, he coordinates the external CMC activities. Roland holds a Ph.D. from the LMU Munich in Chemistry. He joined Origenis in 2008, and has more than 20 years’ experience in synthetic chemistry in many fields of medicinal chemistry, with the major focus on kinase inhibitors.
Nonexecutive Board
Hendrik Liebers,
Chairman of the Board
Hendrik has been active in the biotech industry for more than 25 years now. During that time he held positions as executive, board member and/ or shareholder of multiple companies, mainly in drug development, diagnostics, industrial biotechnology, agrobiotechnology and VC financing. During this time he was instrumental in more than 30 M&A- and Licensing transactions as well as capital raises with top tier funds. As an executive of Probiodrug AG he executed an IPO plus multiple follow on raises. Hendrik holds diplomas in molecular biology and economics, a doctor in medicine and a professorship in economics.
Bernhard Strickler, Member of the Board
Bernhard has studied mechanical engineering and Physics.
Subsequently he was active for several years in low temperature research at Walther Meißner Institut and geophysical measurements in Iceland.
Afterwards he spent over 10 years in software development.
Nowadays he is mainly active as an investor in the field of biotechnology and mechanical engineering.
Werner Buser,
Member of the Board
Werner has been working for more than 30 years in various management position for Best Foods Int. in Europe. After his retirement as Senior Vice President and COO Supply Chain he acted as a “Business Angel” for Start-Ups in a broad range of sectors including software development, health care, flood protection systems, rapid hardening concrete, holiday resorts and biotechnology. He holds a diploma in economics and read “complexity management in supply chain”.
Our Team
